Haemonetics Corporation (HAE): Price and Financial Metrics

Haemonetics Corporation (HAE): $73.74

-0.57 (-0.77%)

POWR Rating

Component Grades














  • Growth is the dimension where HAE ranks best; there it ranks ahead of 95.49% of US stocks.
  • HAE's strongest trending metric is Stability; it's been moving up over the last 178 days.
  • HAE ranks lowest in Momentum; there it ranks in the 18th percentile.

HAE Stock Summary

  • With a one year PEG ratio of 152.21, HAEMONETICS CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 84.21% of US stocks.
  • HAEMONETICS CORP's stock had its IPO on May 10, 1991, making it an older stock than 84.93% of US equities in our set.
  • With a price/earnings ratio of 58.85, HAEMONETICS CORP P/E ratio is greater than that of about 92% of stocks in our set with positive earnings.
  • If you're looking for stocks that are quantitatively similar to HAEMONETICS CORP, a group of peers worth examining would be BCOR, GAMB, KAMN, LXFR, and CMCO.
  • HAE's SEC filings can be seen here. And to visit HAEMONETICS CORP's official web site, go to www.haemonetics.com.

HAE Valuation Summary

  • HAE's price/sales ratio is 3.8; this is 72.73% higher than that of the median Healthcare stock.
  • Over the past 243 months, HAE's price/sales ratio has gone up 1.9.

Below are key valuation metrics over time for HAE.

Stock Date P/S P/B P/E EV/EBIT
HAE 2022-09-09 3.8 5.1 58.3 40.9
HAE 2022-09-08 3.8 5.0 57.2 40.2
HAE 2022-09-07 3.7 5.0 56.5 39.8
HAE 2022-09-06 3.6 4.8 54.9 38.8
HAE 2022-09-02 3.7 4.9 55.9 39.4
HAE 2022-09-01 3.7 5.0 56.4 39.7

HAE Growth Metrics

    Its 2 year price growth rate is now at -41.23%.
  • Its 4 year net income to common stockholders growth rate is now at 230.38%.
  • The 3 year revenue growth rate now stands at 2.65%.
HAE's revenue has moved up $120,191,000 over the prior 70 months.

The table below shows HAE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 1,026.126 215.936 67.706
2022-03-31 993.196 172.263 43.375
2021-12-31 953.223 105.76 22.593
2021-09-30 933.825 109.618 31.243
2021-06-30 903.414 95.313 64.488
2021-03-31 870.463 108.805 79.469

HAE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HAE has a Quality Grade of C, ranking ahead of 50% of graded US stocks.
  • HAE's asset turnover comes in at 0.569 -- ranking 76th of 186 Medical Equipment stocks.
  • CRY, CTSO, and CSII are the stocks whose asset turnover ratios are most correlated with HAE.

The table below shows HAE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-03 0.569 0.460 0.072
2021-04-03 0.581 0.457 0.090
2020-12-26 0.650 0.486 0.150
2020-09-26 0.674 0.485 0.151
2020-06-27 0.738 0.485 0.142
2020-03-28 0.798 0.490 0.116

HAE Price Target

For more insight on analysts targets of HAE, see our HAE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.25 Average Broker Recommendation 1.38 (Strong Buy)

HAE Stock Price Chart Interactive Chart >

Price chart for HAE

HAE Price/Volume Stats

Current price $73.74 52-week high $79.45
Prev. close $74.31 52-week low $43.50
Day low $72.34 Volume 547,500
Day high $73.98 Avg. volume 494,057
50-day MA $72.71 Dividend yield N/A
200-day MA $60.81 Market Cap 3.78B

Haemonetics Corporation (HAE) Company Bio

Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Latest News Stream

Event/Time News Detail
Loading, please wait...

HAE Latest Social Stream

Loading social stream, please wait...

View Full HAE Social Stream

Latest HAE News From Around the Web

Below are the latest news stories about HAEMONETICS CORP that investors may wish to consider to help them evaluate HAE as an investment opportunity.

Haemonetics (HAE) to Offer Two VASCADE Devices in the EU

Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.

Yahoo | September 14, 2022

Haemonetics Earns CE Mark for VASCADE® Vascular Closure Product Portfolio

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced it has earned CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous vascular closure systems. The CE marking will allow Haemonetics to engage in the next steps of country-specific entrance of both products into the European Union (EU) and forms the basis for entry into other geographies that recogni

Yahoo | September 12, 2022

Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 9, 2022

Here's Why You Should Retain Haemonetics (HAE) Stock Now

Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.

Yahoo | September 2, 2022

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

Yahoo | September 2, 2022

Read More 'HAE' Stories Here

HAE Price Returns

1-mo -1.85%
3-mo 13.53%
6-mo 20.31%
1-year 6.12%
3-year -41.44%
5-year 71.81%
YTD 39.03%
2021 -55.33%
2020 3.35%
2019 14.84%
2018 72.26%
2017 44.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5057 seconds.